Lista de obras - Alastair Peter Greystoke

A Pilot Study Assessing the Prognostic Value of CK18 and nDNA Biomarkers in Severe Sepsis Patients

A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours

artículo científico publicado en 2016

A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours

artículo científico publicado en 2006

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours

artículo científico publicado en 2011

A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors

artículo científico publicado en 2016

A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors.

artículo científico publicado en 2014

A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity

scientific article published on 17 October 2013

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).

artículo científico publicado en 2017

An introduction to stratified medicine

artículo científico publicado en 2015

Assessment of diurnal changes and confounding factors that affect circulating cell death biomarker levels: a short communication.

artículo científico publicado en 2013

Biomarker method validation in anticancer drug development

artículo científico publicado en 2007

Biomarkers of cell death applicable to early clinical trials

artículo científico

Cardiopulmonary fitness before and after neoadjuvant chemotherapy in patients with oesophagogastric cancer.

artículo científico publicado en 2018

Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer

article

Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer.

artículo científico publicado en 2017

Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer

artículo científico

Development of a circulating miRNA assay to monitor tumor burden: From mouse to man

artículo científico publicado en 2015

Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer

article

Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy

scientific article published on 23 July 2009

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.

artículo científico publicado en 2015

How many diseases are colorectal cancer?

artículo científico publicado en 2012

Isolation and Extraction of Circulating Tumor DNA from Patients with Small Cell Lung Cancer

artículo científico publicado en 2008

Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs.

artículo científico publicado en 2010

Learning from toxicity patterns in phase I trials during the era of mechanism targeted agents.

artículo científico publicado en 2012

Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.

artículo científico

Metastatic Brain Disease from Non-small Cell Lung Cancer - Getting Back to the Drawing Board.

artículo científico publicado en 2018

SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting

artículo científico publicado en 2017

Serum biomarkers of apoptosis

Spindle cell carcinoma of the head and neck region: treatment and outcomes of 15 patients

artículo científico publicado en 2015

The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers.

artículo científico publicado en 2017

The interaction between prognostic and pharmacodynamic biomarkers.

artículo científico publicado en 2013

The use of circulating biomarkers in early clinical trials in patients with cancer

artículo científico

Transfer and Metabolism of Prostaglandin E2in the Dual Perfused Human Placenta

scientific article published on 01 January 2000

Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer.

artículo científico publicado en 2014

Update on tubulin-binding agents.

artículo científico publicado en 2006

Lista de obras de Alastair Peter Greystoke

A Pilot Study Assessing the Prognostic Value of CK18 and nDNA Biomarkers in Severe Sepsis Patients

A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours

A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours

A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors

A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors.

A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).

An introduction to stratified medicine

Assessment of diurnal changes and confounding factors that affect circulating cell death biomarker levels: a short communication.

Biomarker method validation in anticancer drug development

Biomarkers of cell death applicable to early clinical trials

Cardiopulmonary fitness before and after neoadjuvant chemotherapy in patients with oesophagogastric cancer.

Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer

Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer.

Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer

Development of a circulating miRNA assay to monitor tumor burden: From mouse to man

Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer

Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.

How many diseases are colorectal cancer?

Isolation and Extraction of Circulating Tumor DNA from Patients with Small Cell Lung Cancer

Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs.

Learning from toxicity patterns in phase I trials during the era of mechanism targeted agents.

Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.

Metastatic Brain Disease from Non-small Cell Lung Cancer - Getting Back to the Drawing Board.

SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting

Serum biomarkers of apoptosis

Spindle cell carcinoma of the head and neck region: treatment and outcomes of 15 patients

The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers.

The interaction between prognostic and pharmacodynamic biomarkers.

The use of circulating biomarkers in early clinical trials in patients with cancer

Transfer and Metabolism of Prostaglandin E2in the Dual Perfused Human Placenta

Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer.

Update on tubulin-binding agents.